Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | DRD1 | P21728 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 8/20 | 0.53 |
| ▸ | DRD4 | P21917 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | DRD5 | P21918 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21039946 | 1.00 | DRD2 (0.55) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL24663913 | 0.95 | DRD2 (0.52) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL21039881 | 0.89 | DRD2 (0.65) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL21029534 | 0.89 | DRD2 (0.65) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL22694045 | 0.76 | DRD2 (0.54) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL22694067 | 0.76 | DRD2 (0.53) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL22703548 | 0.75 | DRD2 (0.72) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL22694024 | 0.75 | DRD2 (0.52) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL22703437 | 0.72 | DRD3 (0.62) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL22694040 | 0.72 | DRD3 (0.62) | DRD2DRD1DRD3DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025857-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2024-01-25 | — | — | US | disclosed |
| US-11110110-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | H. LUNDBECK A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20200338102-A1 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2020-10-29 | — | — | US | disclosed |
| US-10729710-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | H. LUNDBECK A/S (DK) | 2020-08-04 | — | — | US | disclosed |
| US-20190160083-A1 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338102-A1 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | COMT, SLC6A2, SLC6A3 | DRD2 24/4885DRD1 107/4885DRD3 98/4885 |
| US-20240025857-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | SLC6A3, CHRNA4, NPY4R | DRD2 21/4885DRD1 33/4885DRD3 54/4885 |
| US-10729710-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | COMT, SLC6A2, SLC6A3 | DRD2 24/4885DRD1 107/4885DRD3 98/4885 |
| US-20190160083-A1 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | COMT, SLC6A2, SLC6A3 | DRD2 24/4885DRD1 107/4885DRD3 98/4885 |
| US-11110110-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | COMT, SLC6A2, SLC6A3 | DRD2 24/4885DRD1 107/4885DRD3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.